iX Biopharma

Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
#11
Rainbow 
FY2020 Result
Rev $0.9m (vs 0.6m)
Gross Loss $0.5m (vs 0.5m)
Net Loss $10m (vs 2m)

The Group is a specialty pharmaceutical company focused on the development and commercialisation of innovative therapies for improving the quality of life of those suffering from pain and other health conditions. The Company leverages its drug formulation expertise and patented sublingual drug delivery technology, WaferiX, to develop products for rapid onset of action with potentially more predictable effects and ease of use. The Group’s nutraceuticals division, Entity Health, is engaged in the development and commercialisation of nutraceutical products that address specific health conditions and improve quality of lifestyles throughout all phases of life.

During the half year ended 30 June 2020 (2H20), the Group has continued to progress the development of its pharmaceutical and nutraceutical product pipeline. 
https://links.sgx.com/FileOpen/iX_4Q20_R...eID=629810

Stay home and stay safe, everyone
Heart
Reply
#12
iX Biopharma enters strategic cooperation framework agreement with China Resources Pharmaceutical Commercial Group Co., Ltd

Singapore, 6 April 2021 – Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) announced that it has entered into a strategic cooperation framework agreement with China Resources Pharmaceutical Commercial Group Co., Ltd. (华润医药商业集团有限公司) ("CRPCG").

Under the Strategic Cooperation Agreement, iX Biopharma and CRPCG will engage in all-round cooperation in respect of iX Biopharma’s pipeline of innovative sublingual pharmaceutical and nutraceutical products in China. The parties will determine the appropriate products and model of cooperation, which may be via licensing or joint venture, and CRPCG will undertake the full scope of operation in China including registration, manufacturing, distribution and promotion.

iX Biopharma has developed a patented drug delivery platform technology, WaferiX. WaferiX delivers drug sublingually via the mucosa for better absorption, faster onset of action and predictable effect. The WaferiX delivery platform is particularly useful for drug repurposing which is a growing trend with a global market worth US$34 billion. Drug repurposing is where existing approved drugs are developed into new drugs targeting different indications or a different route of administration, at a lower development cost and risk.

CRPCG is part of the China Resources Pharmaceutical Group, which is the second largest pharmaceutical manufacturer and one of the three largest pharmaceutical distributors by revenue in China. Through this strategic cooperation, CRPCG will have access to iX Biopharma’s rich pipeline of unique sublingual products, formulated using WaferiX, to meet underserved medical needs across many health conditions. By leveraging on each other’s strengths and capabilities, both parties will cooperate to seize the immense opportunities in the China market.

More details in https://links.sgx.com/1.0.0/corporate-an...202021.pdf
Specuvestor: Asset - Business - Structure.
Reply


Forum Jump:


Users browsing this thread: 1 Guest(s)